Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Non-Current Deferred Tax Liability (2023 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Non-Current Deferred Tax Liability for 3 consecutive years, with $6.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Deferred Tax Liability fell 56.95% to $6.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.9 million, a 56.95% decrease, with the full-year FY2025 number at $6.9 million, down 56.95% from a year prior.
  • Non-Current Deferred Tax Liability was $6.9 million for Q4 2025 at Cartesian Therapeutics, down from $16.1 million in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $16.1 million in Q4 2024 to a low of $6.9 million in Q4 2025.
  • A 3-year average of $15.0 million and a median of $15.9 million in 2023 define the central range for Non-Current Deferred Tax Liability.
  • Peak YoY movement for Non-Current Deferred Tax Liability: grew 1.82% in 2024, then crashed 56.95% in 2025.
  • Cartesian Therapeutics' Non-Current Deferred Tax Liability stood at $15.9 million in 2023, then grew by 1.82% to $16.1 million in 2024, then plummeted by 56.95% to $6.9 million in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Non-Current Deferred Tax Liability are $6.9 million (Q4 2025), $16.1 million (Q3 2025), and $16.1 million (Q2 2025).